Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.57 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 3/20 | 0.47 |
| ▸ | GAK | O14976 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.44 |
| ▸ | STK10 | O94804 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732085 | 0.82 | PIK3CA (0.62) | PIK3CAAKT1PIK3CDPIK3CBMTOR | |
| SCHEMBL730195 | 0.80 | PIK3CA (0.84) | PIK3CAAKT1GAKPIK3CDRPS6KA4 | |
| SCHEMBL730633 | 0.79 | PIK3CA (0.62) | PIK3CAAKT1GAKPIK3CDRPS6KA4 | |
| SCHEMBL730188 | 0.78 | PIK3CA (0.87) | PIK3CAAKT1GAKPIK3CDRPS6KA4 | |
| SCHEMBL731933 | 0.76 | PIK3CA (0.62) | PIK3CAAKT1GAKSLC22A12PIK3CD | |
| SCHEMBL12850664 | 0.76 | PIK3CA (0.62) | PIK3CAAKT1GAKPIK3CDRPS6KA4 | |
| SCHEMBL9909160 | 0.75 | SLC22A12 (0.58) | PIK3CASLC22A12MAPKAPK2CCNB2CDK1 | |
| SCHEMBL14539006 | 0.74 | ALOX5 (0.57) | PIK3CASLC22A12AAK1MAPK14CCNB2 | |
| SCHEMBL31097132 | 0.74 | ALOX5 (0.57) | PIK3CASLC22A12AAK1MAPK14CCNB2 | |
| SCHEMBL3428078 | 0.74 | GAK (0.42) | GAKSLC22A12CCNCCDK8RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2596793-B1 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2014-10-02 | — | — | US | disclosed |
| US-8785433-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140100234-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633187-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| CN-101754759-B | Quinoline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORP | 2013-10-09 | — | — | CN | disclosed |
| EP-2596793-A1 | Quinoline derivatives as PI3 kinase inhibitors | Glaxosmithkline LLC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8404837-B2 | Quinoline derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120165321-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-8138347-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100168100-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-06-17 | — | — | US | disclosed |
| EP-2192902-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | PIK3CA 13/4885PKN1 512/4885PKN2 475/4885 |
| US-20140100234-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885PKN1 1216/4885PKN2 1135/4885 |
| US-20100168100-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | PIK3CA 13/4885PKN1 512/4885PKN2 475/4885 |
| US-20120165321-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885PKN1 1216/4885PKN2 1135/4885 |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885PKN1 1216/4885PKN2 1135/4885 |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CA 6/4885PKN1 1216/4885PKN2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.